Skip to main content

Table 5 Primary (mean change in HbA1c from baseline at study end) and key secondary outcomes of the SURPASS 1–5 clinical trials with the obtained results

From: Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

Study name Primary/secondary endpoint(s) (weeks) Mean HbA1c at baseline (%) Mean HbA1c reduction from baseline (%) with tirzepatide 5/10/15 mg Percentage of patients who met +HbA1c < 7.0%; #HbA1c ≤ 6.5% and *HbA1c < 5.7% with tirzepatide 5/10/15 mg Mean body weight at baseline (kg) Mean reduction in body weight from baseline (kg) with tirzepatide 5/10/15 mg Percentage of patients who met a weight loss of a≥ 5%; b≥ 10%; and c≥ 15% with tirzepatide 5/10/15 mg
SURPASS-1
[38]
40 7.94 1.87/1.89/2.07 +87/92/88
#82/81/86
*34/31/52
85.9 7.0/7.8/9.5 a67/78/77
b31/40 /47
c13/17/27
SURPASS-2
[39]
40 8.28 2.01/2.24/2.30 +82/86/86
#69/77/80
*27/40/46
93.7 7.6/9.3/11.2 a65/76/80
b34/47/57
c15/24/36
SURPASS-3
[40]
52 8.17 1.93/2.20/2.37 +82/90/93
#71/80/85
*26/39/48
94.3 7.5/10.7/12.9 a66/84/88
b37/56/69
c13/28/43
SURPASS-4
[41]
52 8.52 2.24/2.43/2.58 +81/88/91
#66/76/81
*23/33/43
90.3 7.1/9.5/11.7 a63/78/85
b36/53/66
c14/24/37
SURPASS-5
[42]
40 8.31 2.11/2.40/2.34 +87/90/85
#74/86/80
*24/42/50
95.2 5.4/7.5/8.8 a56/68/85
b24/49/48
c8/28/27
  1. Results of the SURPASS-6 trial are not yet available